Tsingyuan Ventures

Tsingyuan Ventures, accessible via foothill.ventures/tsingyuan, is the Tsinghua alumni-aligned arm of the Foothill Ventures platform, historically focused on early-stage US-China bridge investments in deep tech and life sciences. While the input record does not specify stages or check sizes, the platform’s broader public profile points to seed and Series A positions in biotech, medtech, AI, and frontier hardware founded by Tsinghua-affiliated entrepreneurs. For healthcare AI founders, this is most relevant if you have a credible China angle: a co-founder, a clinical site, a manufacturing partner, or a market entry plan that benefits from a network in Beijing and the Greater Bay Area. Pure US-only digital health plays without that bridge are a weaker fit since several stronger California seed funds will compete for the same allocation with deeper domestic provider networks. Likely check sizes for a fund in this category are USD 500K to USD 3M, with selective follow-on into priced rounds. Founders building diagnostics, drug discovery platforms, computational biology, medical imaging AI, or surgical robotics with a Tsinghua research linkage should prioritize this firm. Anyone running a US-only payer-facing SaaS company will get less from the relationship than a China-connected technical founder. Entry path is a warm introduction through the Tsinghua alumni network or Foothill portfolio, plus a LinkedIn message to a partner emphasizing the technical edge and the bilateral angle. Have a clear answer on regulatory strategy in both jurisdictions before the first call.